These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 28124463)

  • 21. [FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA].
    Ben Yakov G; Montano D; Abu Freha N; Etzion O; Dizingof V; Mushkalo A; Shwarts D; Monitin S; Takchick A; Zilberman D; Sikuler E; Fich A
    Harefuah; 2016 May; 155(5):272-5, 324, 323. PubMed ID: 27526553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.
    Signorovitch JE; Betts KA; Song Y; Sorg RA; Li J; Behl AS; Kalsekar A
    J Comp Eff Res; 2015 Nov; 4(6):593-605. PubMed ID: 26159375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
    Pearlman BL; Ehleben C; Perrys M
    Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.
    Muir AJ; Poordad F; Lalezari J; Everson G; Dore GJ; Herring R; Sheikh A; Kwo P; Hézode C; Pockros PJ; Tran A; Yozviak J; Reau N; Ramji A; Stuart K; Thompson AJ; Vierling J; Freilich B; Cooper J; Ghesquiere W; Yang R; McPhee F; Hughes EA; Swenson ES; Yin PD
    JAMA; 2015 May; 313(17):1736-44. PubMed ID: 25942724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.
    Yang SS; Kao JH
    Hepatol Int; 2016 Mar; 10(2):258-66. PubMed ID: 26542068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.
    Cento V; Nguyen THT; Di Carlo D; Biliotti E; Gianserra L; Lenci I; Di Paolo D; Calvaruso V; Teti E; Cerrone M; Romagnoli D; Melis M; Danieli E; Menzaghi B; Polilli E; Siciliano M; Nicolini LA; Di Biagio A; Magni CF; Bolis M; Antonucci FP; Di Maio VC; Alfieri R; Sarmati L; Casalino P; Bernardini S; Micheli V; Rizzardini G; Parruti G; Quirino T; Puoti M; Babudieri S; D'Arminio Monforte A; Andreoni M; Craxì A; Angelico M; Pasquazzi C; Taliani G; Guedj J; Perno CF; Ceccherini-Silberstein F
    PLoS One; 2017; 12(5):e0177352. PubMed ID: 28545127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ideal oral combinations to eradicate HCV: The role of ribavirin.
    Hézode C; Bronowicki JP
    J Hepatol; 2016 Jan; 64(1):215-25. PubMed ID: 26409316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals.
    Huang Y; Li MH; Hou M; Xie Y
    Hepatobiliary Pancreat Dis Int; 2017 Oct; 16(5):470-479. PubMed ID: 28992878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals.
    Serfaty L
    Liver Int; 2015 Jan; 35 Suppl 1():18-20. PubMed ID: 25529083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
    Kowdley KV; Lawitz E; Crespo I; Hassanein T; Davis MN; DeMicco M; Bernstein DE; Afdhal N; Vierling JM; Gordon SC; Anderson JK; Hyland RH; Dvory-Sobol H; An D; Hindes RG; Albanis E; Symonds WT; Berrey MM; Nelson DR; Jacobson IM
    Lancet; 2013 Jun; 381(9883):2100-7. PubMed ID: 23499440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
    Marcellin P; Cooper C; Balart L; Larrey D; Box T; Yoshida E; Lawitz E; Buggisch P; Ferenci P; Weltman M; Labriola-Tompkins E; Le Pogam S; Nájera I; Thomas D; Hooper G; Shulman NS; Zhang Y; Navarro MT; Lim CY; Brunda M; Terrault NA; Yetzer ES
    Gastroenterology; 2013 Oct; 145(4):790-800.e3. PubMed ID: 23811112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
    Lawitz E; Lalezari JP; Hassanein T; Kowdley KV; Poordad FF; Sheikh AM; Afdhal NH; Bernstein DE; Dejesus E; Freilich B; Nelson DR; Dieterich DT; Jacobson IM; Jensen D; Abrams GA; Darling JM; Rodriguez-Torres M; Reddy KR; Sulkowski MS; Bzowej NH; Hyland RH; Mo H; Lin M; Mader M; Hindes R; Albanis E; Symonds WT; Berrey MM; Muir A
    Lancet Infect Dis; 2013 May; 13(5):401-8. PubMed ID: 23499158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.
    Suzuki Y; Ikeda K; Suzuki F; Toyota J; Karino Y; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hu W; Eley T; McPhee F; Hughes E; Kumada H
    J Hepatol; 2013 Apr; 58(4):655-62. PubMed ID: 23183526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
    Pascale A; Serfaty L
    J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice.
    Kan H; Hiraga N; Imamura M; Hayes CN; Uchida T; Miyaki E; Tsuge M; Abe H; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
    Antivir Ther; 2016; 21(4):307-15. PubMed ID: 26562322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.
    Shiffman ML; Suter F; Bacon BR; Nelson D; Harley H; Solá R; Shafran SD; Barange K; Lin A; Soman A; Zeuzem S;
    N Engl J Med; 2007 Jul; 357(2):124-34. PubMed ID: 17625124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.
    Gordon SC; Reddy KR; Jacobson IM; Poordad F; Bronowicki JP; Bacon B; Buti M; Hu KQ; Pedicone LD; Burroughs M; Brass CA; Albrecht JK; Lawitz EJ
    J Clin Gastroenterol; 2014; 48(5):435-43. PubMed ID: 24177376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.
    Suzuki F; Toyota J; Ikeda K; Chayama K; Mochida S; Hayashi N; Ishikawa H; Miyagoshi H; Hu W; McPhee F; Hughes EA; Kumada H
    Antivir Ther; 2014; 19(5):491-9. PubMed ID: 24451122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HCV direct-acting antiviral agents: the best interferon-free combinations.
    Schinazi R; Halfon P; Marcellin P; Asselah T
    Liver Int; 2014 Feb; 34 Suppl 1(Suppl 1):69-78. PubMed ID: 24373081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.